英国早孕期子痫前期筛查的成本效果分析
本研究采用决策树模型,比较FMF策略与NICE策略在英国早孕期筛查早产子痫前期的成本效果。结论认为FMF策略更具成本效果。
要点
- FMF策略相比NICE策略每万例节省3191英镑,增加0.92个QALY。
- FMF策略每避免一例早产子痫前期可节省199英镑。
- FMF策略在3%、5%、7%发病率及75%、100%阿司匹林依从性下均具成本效果。
核心结论
- 在英国早孕期早产子痫前期筛查中,FMF策略相比NICE策略更具成本效果。
研究设计与样本
- 成本效果分析,采用决策树模型。
- 从英国国家医疗服务体系和个人社会服务视角。
- 假设高风险孕妇每日服用150mg阿司匹林至36周。
主要发现
- FMF策略相比NICE策略每万例节省3191英镑并增加0.92个QALY(优势ICER)。
- FMF策略每避免一例早产子痫前期节省199英镑。
- FMF策略在3%、5%、7%子痫前期发病率及75%、100%阿司匹林依从性下均具成本效果。
- 基础案例FMF策略(母体因素+MAP+UtA-PI+PlGF)是最具临床效果的选择。
关键数值与推荐
- FMF策略组成:母体因素、平均动脉压(MAP)、子宫动脉搏动指数(UtA-PI)和胎盘生长因子(PlGF)。
- NICE推荐的筛查策略作为对照。
- 高风险孕妇每日服用150mg阿司匹林至36周。
临床怎么用
- 在英国医疗体系中,采用FMF策略进行早孕期早产子痫前期筛查可节省成本并改善健康结局。
- FMF策略在多种子痫前期发病率和阿司匹林依从性场景下均保持成本效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the cost-effectiveness of the Fetal Medicine Foundation (FMF) strategy, compared with the National Institute for Health and Care Excellence (NICE) strategy, for first-trimester screening for preterm preeclampsia (PE) in the United Kingdom (UK). DESIGN: Cost-effectiveness analysis. SETTING: UK National Health Service and personal social services perspective. POPULATION: A total of 10 000 simulated patients with singleton pregnancies at 11-13 weeks' gestation, across a lifetime time horizon. METHODS: A decision-tree model was developed to perform a cost-effectiveness analysis. In the base-case analysis, NICE-recommended screening was compared with FMF screening, using maternal factors, mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI) and placental growth factor (PlGF). The model assumed that patients identified as high-risk for PE were prescribed 150 mg aspirin daily until 36 weeks' gestation. Scenario analyses varied PE incidence, aspirin adherence and biomarker combinations of FMF strategy components. MAIN OUTCOME MEASURE: Incremental cost-effectiveness ratios (ICERs) were calculated using incremental costs and quality-adjusted life years (QALYs). Dominant ICERs demonstrated lower costs and higher QALYs. RESULTS: Compared with NICE-recommended screening, the FMF strategy demonstrated a cost-saving of £3191 and QALY gain of 0.92 per 10 000 patients (dominant ICER), with a cost-saving of £199 per preterm PE case avoided. In scenario analyses, the FMF strategy was cost-effective across 3%, 5% and 7% PE incidence, and 75% and 100% aspirin adherence. The base-case FMF strategy (maternal factors + MAP + UtA-PI + PlGF) was the most clinically effective option. CONCLUSIONS: The FMF strategy was more cost-effective versus the NICE strategy for first-trimester preterm PE screening in the UK.
引用
- Ani MA, Poon LC, Magee LA, et al. First Trimester Screening for Preterm Preeclampsia in the United Kingdom: A Cost-Effectiveness Analysis. BJOG. 2026. PMID: 42383395. doi:10.1111/1471-0528.70294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。